However, TACC3 siRNA knockdown did not influence doxorubicin sensitivity in the breast cancer cell lines we tested, although we cannot rule out the possibility that this gene may contribute to the observed association with survival in vivo. The gene discussed is TACC3; the disease is breast cancer.